This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Type II glycogen storage disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pompe disease

  • also referred to as acid maltase deficiency (AMD) or glycogen storage disease type II (GSDII)

  • w as originally described by PJ Pompe, a Dutch pathologist, in 1932

  • is an autosomal recessive disorder caused by a deficiency of the lysosomal enzyme acid-alpha-glucosidase (GAA)

  • was the first recognized lysosomal storage disease and is the only glycogen storage disease that is also a lysosomal storage disease

  • lysosomal glycogen accumulates in many tissues with skeletal, cardiac, and smooth muscle most prominently involved

  • severity varies by age of onset, organ involvement including degree and severity of muscular involvement (skeletal, respiratory, cardiac), and rate of progression

  • has also been classified as a neuromuscular disease or metabolic myopathy (due to the presence of weakness and hypotonia)

  • incidence data are limited with reports ranging from 1 in 14,000 to 1 in 300,000 depending upon ethnicity or the geographic area studied (1)

Reference:

  • Kishnani PS et al..Pompe disease diagnosis and management guideline. Genet Med. 2006 May;8(5):267-88.
  • Kohler L, Puertollano R, Raben N. Pompe Disease: From Basic Science to Therapy. Neurotherapeutics. 2018 Oct;15(4):928-942

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.